CN120290577A - 用于治疗杜氏肌营养不良的抗flt-1抗体 - Google Patents
用于治疗杜氏肌营养不良的抗flt-1抗体 Download PDFInfo
- Publication number
- CN120290577A CN120290577A CN202510178279.0A CN202510178279A CN120290577A CN 120290577 A CN120290577 A CN 120290577A CN 202510178279 A CN202510178279 A CN 202510178279A CN 120290577 A CN120290577 A CN 120290577A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- flt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144251P | 2015-04-07 | 2015-04-07 | |
| US62/144,251 | 2015-04-07 | ||
| US201662307645P | 2016-03-14 | 2016-03-14 | |
| US62/307,645 | 2016-03-14 | ||
| CN201680032814.0A CN107787330B (zh) | 2015-04-07 | 2016-04-07 | 用于治疗杜氏肌营养不良的抗flt-1抗体 |
| PCT/US2016/026352 WO2016164528A1 (en) | 2015-04-07 | 2016-04-07 | Anti-flt-1 antibodies for treating duchenne muscular dystrophy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680032814.0A Division CN107787330B (zh) | 2015-04-07 | 2016-04-07 | 用于治疗杜氏肌营养不良的抗flt-1抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120290577A true CN120290577A (zh) | 2025-07-11 |
Family
ID=55754471
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210037246.0A Active CN114539408B (zh) | 2015-04-07 | 2016-04-07 | 用于治疗杜氏肌营养不良的抗flt-1抗体 |
| CN201680032814.0A Active CN107787330B (zh) | 2015-04-07 | 2016-04-07 | 用于治疗杜氏肌营养不良的抗flt-1抗体 |
| CN202510178279.0A Pending CN120290577A (zh) | 2015-04-07 | 2016-04-07 | 用于治疗杜氏肌营养不良的抗flt-1抗体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210037246.0A Active CN114539408B (zh) | 2015-04-07 | 2016-04-07 | 用于治疗杜氏肌营养不良的抗flt-1抗体 |
| CN201680032814.0A Active CN107787330B (zh) | 2015-04-07 | 2016-04-07 | 用于治疗杜氏肌营养不良的抗flt-1抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10787515B2 (enExample) |
| EP (2) | EP3280734B1 (enExample) |
| JP (3) | JP6993880B2 (enExample) |
| CN (3) | CN114539408B (enExample) |
| AU (2) | AU2016246722B2 (enExample) |
| ES (1) | ES2910783T3 (enExample) |
| MA (1) | MA41899A (enExample) |
| MX (1) | MX2017012828A (enExample) |
| PL (1) | PL3280734T3 (enExample) |
| WO (1) | WO2016164528A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41899A (fr) | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
| WO2020108497A1 (zh) * | 2018-11-29 | 2020-06-04 | 和铂医药（香港）有限公司 | 一种抗pd-l1抗体制剂 |
| JP7753186B2 (ja) * | 2019-08-02 | 2025-10-14 | シーティーティーキュー－アケソ（シャンハイ） バイオメド テク カンパニー リミテッド | 抗ｐｄ－１抗体およびその医学的使用 |
| CN114230666B (zh) * | 2021-12-20 | 2022-09-02 | 南京诺唯赞生物科技股份有限公司 | 一种t7 rna聚合酶的单克隆抗体及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8287864B2 (en) * | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| WO2006055809A2 (en) * | 2004-11-18 | 2006-05-26 | Imclone Systems Incorporated | Antibodies against vascular endothelial growth factor receptor-1 |
| JP5823871B2 (ja) | 2008-12-10 | 2015-11-25 | アブリンクス エン．ヴェー． | 血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US9592331B2 (en) * | 2011-02-07 | 2017-03-14 | Aggamin Llc | Methods and systems for treating eclampsia or pre-eclampsia |
| ES2676406T3 (es) * | 2013-01-28 | 2018-07-19 | Shire Human Genetic Therapies, Inc. | Anticuerpos anti-Flt-1 en el tratamiento de la distrofia muscular de Duchenne |
| TW201517916A (zh) | 2013-03-15 | 2015-05-16 | Lilly Co Eli | Ｖｅｇｆｒ１抗體之治療用途 |
| MA41899A (fr) | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
-
2016
- 2016-04-06 MA MA041899A patent/MA41899A/fr unknown
- 2016-04-07 CN CN202210037246.0A patent/CN114539408B/zh active Active
- 2016-04-07 EP EP16716795.6A patent/EP3280734B1/en active Active
- 2016-04-07 MX MX2017012828A patent/MX2017012828A/es unknown
- 2016-04-07 WO PCT/US2016/026352 patent/WO2016164528A1/en not_active Ceased
- 2016-04-07 PL PL16716795T patent/PL3280734T3/pl unknown
- 2016-04-07 JP JP2017552899A patent/JP6993880B2/ja active Active
- 2016-04-07 CN CN201680032814.0A patent/CN107787330B/zh active Active
- 2016-04-07 AU AU2016246722A patent/AU2016246722B2/en active Active
- 2016-04-07 ES ES16716795T patent/ES2910783T3/es active Active
- 2016-04-07 US US15/564,976 patent/US10787515B2/en active Active
- 2016-04-07 EP EP22153298.9A patent/EP4056593A1/en active Pending
- 2016-04-07 CN CN202510178279.0A patent/CN120290577A/zh active Pending
-
2020
- 2020-08-12 US US16/991,762 patent/US20210206860A1/en not_active Abandoned
-
2021
- 2021-12-10 JP JP2021200631A patent/JP7456989B2/ja active Active
-
2022
- 2022-01-25 AU AU2022200466A patent/AU2022200466B2/en active Active
-
2023
- 2023-03-23 US US18/189,065 patent/US12435146B2/en active Active
-
2024
- 2024-03-14 JP JP2024039804A patent/JP7741225B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3280734T3 (pl) | 2022-07-04 |
| EP3280734A1 (en) | 2018-02-14 |
| US12435146B2 (en) | 2025-10-07 |
| CN107787330B (zh) | 2022-02-01 |
| JP2018518153A (ja) | 2018-07-12 |
| CN107787330A (zh) | 2018-03-09 |
| ES2910783T3 (es) | 2022-05-13 |
| WO2016164528A9 (en) | 2017-01-12 |
| BR112017021414A2 (pt) | 2018-07-03 |
| AU2022200466A1 (en) | 2022-02-17 |
| JP2022040124A (ja) | 2022-03-10 |
| AU2016246722A1 (en) | 2017-10-26 |
| HK1249912A1 (en) | 2018-11-16 |
| US20240076387A1 (en) | 2024-03-07 |
| MA41899A (fr) | 2018-02-13 |
| MX2017012828A (es) | 2018-06-19 |
| US20180072806A1 (en) | 2018-03-15 |
| US20210206860A1 (en) | 2021-07-08 |
| JP6993880B2 (ja) | 2022-01-14 |
| JP7741225B2 (ja) | 2025-09-17 |
| JP7456989B2 (ja) | 2024-03-27 |
| CN114539408B (zh) | 2025-03-11 |
| WO2016164528A1 (en) | 2016-10-13 |
| US10787515B2 (en) | 2020-09-29 |
| EP3280734B1 (en) | 2022-01-26 |
| AU2016246722B2 (en) | 2021-10-28 |
| CN114539408A (zh) | 2022-05-27 |
| EP4056593A1 (en) | 2022-09-14 |
| JP2024069463A (ja) | 2024-05-21 |
| CA2981954A1 (en) | 2016-10-13 |
| AU2022200466B2 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2549959T3 (es) | Anticuerpos monoclonales contra la proteína RGM A y usos de los mismos | |
| US20210277097A1 (en) | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration | |
| JP7741225B2 (ja) | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 | |
| JP7051150B2 (ja) | 気分障害の治療及び診断のための抗－配列類似性１９を持つファミリー、メンバーａ５抗体の用途 | |
| JP2019023230A (ja) | デュシェンヌ型筋ジストロフィーの治療における抗−ｆｌｔ−１抗体 | |
| CA2981954C (en) | Anti-flt-1 antibodies for treating duchenne muscular dystrophy | |
| JP2022526493A (ja) | 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法 | |
| HK40079861A (en) | Anti-flt-1 antibodies for treating duchenne muscular dystrophy | |
| HK1249912B (en) | Anti-flt-1 antibodies for treating duchenne muscular dystrophy | |
| BR112017021414B1 (pt) | Anticorpos anti-flt-1 e composição farmacêutica compreendendo os referidos anticorpos | |
| BR122024023570A2 (pt) | Polinucleotídeo que codifica um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno, composição farmacêutica, usos relacionados, vetor de expressão, célula isolada e anticorpos anti-flt-1 ou seu fragmento de ligação ao antígeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |